| answer text |
<p>The United Kingdom participates in various transparency initiatives, including
the European Integrated Price Information Database, the World Health Organization’s
Pharmaceutical Pricing Reimbursement Information Network, and the Global Fund Price
and Quality Database. The UK has a long-established and globally-recognised track
record of assessing the price of new, innovative medicines according to their clinical
value, rather than pricing by their development costs or international reference prices.</p><p>We
believe that is the right approach: ensuring the development of the best medicines
in areas of high unmet need are rewarded. The Government could not, therefore, agree
to a resolution which had the potential to increase medicines prices and reduce patient
access, by reducing the ability of the National Health Service to undertake commercial
negotiations with pharmaceutical companies on the price of new medicines.</p><p>The
approach taken by the NHS has meant we were the first country in Europe to offer innovative
CAR-T therapies, alongside many other new medicines.</p><p> </p><p> </p><p> </p>
|
|
